The cumulative net sales for the second quarter of the fiscal year ending September 2026 have been revised upward by 1.3% from the previous forecast to JPY 29,420 million, and operating income by 47.0% to JPY 4,100 million. Conversely, net income attributable to owners of parent has been revised downward by 55.4% to JPY 860 million due to the recording of a stock valuation loss.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4554","jir_company_name":"Fuji Pharmaceutical Industries Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4554-20260205-03.pdf","jir_short_summary":"The cumulative net sales for the second quarter of the fiscal year ending September 2026 have been revised upward by 1.3% from the previous forecast to JPY 29,420 million, and operating income by 47.0% to JPY 4,100 million. Conversely, net income attributable to owners of parent has been revised downward by 55.4% to JPY 860 million due to the recording of a stock valuation loss.","jir_summary":"### Details of Earnings Guidance Revision\nFuji Pharmaceutical Industries Co., Ltd. has revised its earnings guidance for the cumulative second quarter period and full fiscal year ending September 2026. The cumulative second quarter net sales were revised upward to JPY 29,420 million (1.3% increase from the previous forecast), operating income to JPY 4,100 million (47.0% increase), and ordinary income to JPY 3,970 million (49.2% increase). Conversely, net income attributable to owners of parent for the quarter was revised downward to JPY 860 million (55.4% decrease). For the full year, net sales were revised upward to JPY 59,250 million (3.1% increase), operating income to JPY 6,120 million (10.9% increase), and ordinary income to JPY 5,880 million (12.2% increase), while net income was revised downward to JPY 2,240 million (41.2% decrease).\n\n### Reasons for Revision and Future Outlook\nDue to stronger-than-expected sales of core products leading to improved profitability, forecasts for net sales, operating income, and ordinary income have been revised upward. Conversely, a stock valuation loss of JPY 2,457 million was recorded stemming from a significant decline in the share price of Alvotech Holding S.A., a Nasdaq-listed company, resulting in a downward revision of net income forecasts. The holding of Alvotech shares is part of the growth strategy for the biosimilar business, and collaboration with the company is being strengthened. There is no change to the dividend forecast.","jir_financial_highlights":"Net Sales (Cumulative Second Quarter): JPY 29,420 million (1.3% increase from previous forecast)\nOperating Income (Cumulative Second Quarter): JPY 4,100 million (47.0% increase from previous forecast)\nOrdinary Income (Cumulative Second Quarter): JPY 3,970 million (49.2% increase from previous forecast)\nNet Income Attributable to Owners of Parent (Cumulative Second Quarter): JPY 860 million (55.4% decrease from previous forecast)\nNet Sales (Full Year): JPY 59,250 million (3.1% increase from previous forecast)\nOperating Income (Full Year): JPY 6,120 million (10.9% increase from previous forecast)\nOrdinary Income (Full Year): JPY 5,880 million (12.2% increase from previous forecast)\nNet Income Attributable to Owners of Parent (Full Year): JPY 2,240 million (41.2% decrease from previous forecast)","jir_category":"","jir_hashtags":"#FujiPharmaceuticalIndustries, #EarningsGuidanceRevision, #JapaneseStocks","jir_key_figures":"Second Quarter Net Sales: JPY 29,420 million (1.3% increase from previous forecast)\nSecond Quarter Operating Income: JPY 4,100 million (47.0% increase from previous forecast)\nStock Valuation Loss: JPY 2,457 million (valuation loss on Alvotech shares)","jir_meta_title":"Fuji Pharmaceutical Industries Revises FY2026 Earnings Guidance with 3.1% Increase in Net Sales But 41.2% Decrease in Net Income","jir_meta_description":"Fuji Pharmaceutical Industries has upwardly revised net sales and operating income forecasts for FY2026, supported by strong core product performance, while net income is forecasted to decline significantly due to a stock valuation loss related to Alvotech shares.","jir_og_title":"Fuji Pharmaceutical Industries Revises FY2026 Earnings Guidance: Sales Increase but Net Income Declines","jir_og_description":"Upward revision of net sales and operating income driven by strong core product sales; net income expected to decline due to recording of stock valuation loss.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Comparison of Revised Net Sales Forecasts (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Previous Forecast (Q2)\\\",\\\"Revised Forecast (Q2)\\\",\\\"Previous Forecast (Full Year)\\\",\\\"Revised Forecast (Full Year)\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[29030,29420,57490,59250],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Comparison of Revised Operating Income Forecasts (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Previous Forecast (Q2)\\\",\\\"Revised Forecast (Q2)\\\",\\\"Previous Forecast (Full Year)\\\",\\\"Revised Forecast (Full Year)\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[2790,4100,5520,6120],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"ordinary_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Comparison of Revised Ordinary Income Forecasts (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Previous Forecast (Q2)\\\",\\\"Revised Forecast (Q2)\\\",\\\"Previous Forecast (Full Year)\\\",\\\"Revised Forecast (Full Year)\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Ordinary Income\\\",\\\"data\\\":[2660,3970,5240,5880],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Comparison of Revised Net Income Attributable to Owners of Parent Forecasts (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Previous Forecast (Q2)\\\",\\\"Revised Forecast (Q2)\\\",\\\"Previous Forecast (Full Year)\\\",\\\"Revised Forecast (Full Year)\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[1930,860,3810,2240],\\\"backgroundColor\\\":\\\"#76b7b2\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"eps_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Comparison of Revised Quarterly and Full Year EPS Forecasts (JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Previous Forecast (Q2)\\\",\\\"Revised Forecast (Q2)\\\",\\\"Previous Forecast (Full Year)\\\",\\\"Revised Forecast (Full Year)\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly EPS\\\",\\\"data\\\":[78.92,35.15,null,null],\\\"borderColor\\\":\\\"#59a14f\\\",\\\"fill\\\":false},{\\\"label\\\":\\\"Full Year EPS\\\",\\\"data\\\":[null,null,155.79,91.54],\\\"borderColor\\\":\\\"#edc948\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":17504,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-24827","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n